Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients

Differences in clinical effectiveness between angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in the primary treatment of hypertension are unknown. The aim of this retrospective cohort study was to assess the prevention of type 2 diabetes and cardiovascular...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Hasvold, L P, Bodegård, J, Thuresson, M, Stålhammar, J, Hammar, N, Sundström, J, Russell, D, Kjeldsen, S E
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2014
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4191159/
https://ncbi.nlm.nih.gov/pubmed/25211055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jhh.2014.43
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky